{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:56:17Z","timestamp":1788339377942,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Snake and insect venoms have been demonstrated to have beneficial effects in the treatment of certain diseases including drug resistant human immunodeficiency virus (HIV) infection. We evaluated and hypothesized the probable mechanisms of venoms against HIV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Previous literatures published over a period of 30 years (1979-2009) were searched using the key words snake venom, insect venom, mechanisms and HIV. Mechanisms were identified and discussed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results &amp; Conclusion<\/jats:title>\n            <jats:p>With reference to mechanisms of action, properties and components of snake venom such as sequence homology and enzymes (protease or L- amino acid oxidase) may have an effect on membrane protein and\/or act against HIV at multiple levels or cells carrying HIV virus resulting in enhanced effect of anti-retroviral therapy (ART). This may cause a decrease in viral load and improvement in clinical as well as immunological status. Insect venom and human Phospholipase A<jats:sub>2<\/jats:sub> (PLA<jats:sub>2<\/jats:sub>) have potential anti-viral activity through inhibition of virion entry into the cells. However, all these require further evaluation in order to establish its role against HIV as an independent one or as a supplement.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1742-6405-6-25","type":"journal-article","created":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T07:13:58Z","timestamp":1258614838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review"],"prefix":"10.1186","volume":"6","author":[{"given":"Ramachandran","family":"Meenakshisundaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Sweni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponniah","family":"Thirumalaikolundusubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,19]]},"reference":[{"issue":"24","key":"124_CR1","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1007\/s00018-006-6315-0","volume":"63","author":"D Koh","year":"2006","unstructured":"Koh D, Armugam A, Jeyaseelan K: Snake venom components and their applications in biomedicine. Cell Mol Life Sci. 2006, 63 (24): 3030-3041. 10.1007\/s00018-006-6315-0","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"124_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1096\/fj.03-1398bkt","volume":"18","author":"M Patlak","year":"2004","unstructured":"Patlak M: From viper's venom to drug design: treating hypertension. FASEB J. 2004, 18 (3): 421- 10.1096\/fj.03-1398bkt","journal-title":"FASEB J"},{"issue":"3-6","key":"124_CR3","first-page":"211","volume":"31","author":"NA Marsh","year":"2001","unstructured":"Marsh NA: Diagnostic uses of snake venom. Haemostasis. 2001, 31 (3-6): 211-217.","journal-title":"Haemostasis"},{"issue":"4","key":"124_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1745-7254.2006.00293.x","volume":"27","author":"ZX Chen","year":"2006","unstructured":"Chen ZX, Zhang HL, Gu ZL, Chen BW, Han R, Reid PF, Raymond LN, Qin ZH: A long-form alpha-neurotoxin from cobra venom produces potent opioid-independent analgesia. Acta Pharmacol Sin. 2006, 27 (4): 402-408. 10.1111\/j.1745-7254.2006.00293.x","journal-title":"Acta Pharmacol Sin"},{"issue":"11","key":"124_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/0041-0101(95)00096-5","volume":"33","author":"XC Pu","year":"1995","unstructured":"Pu XC, Wong PT, Gopalakrishnakone P: A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah). Toxicon. 1995, 33 (11): 1425-1431. 10.1016\/0041-0101(95)00096-5","journal-title":"Toxicon"},{"issue":"2","key":"124_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1432-1033.1993.tb17946.x","volume":"214","author":"G Faure","year":"1993","unstructured":"Faure G, Harvey AL, Thomson E, Saliou B, Radvyani F, Bon C: Comparison of crotoxin isoforms reveals that stability of the complex plays a major role in its pharmacological action. Eur J Biochem. 1993, 214 (2): 491-496. 10.1111\/j.1432-1033.1993.tb17946.x","journal-title":"Eur J Biochem"},{"issue":"4","key":"124_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4103\/0256-4947.51714","volume":"28","author":"AA Alrajhi","year":"2008","unstructured":"Alrajhi AA, Almohaizeie A: Snake venom preparation for drug-resistant human immunodeficiency virus. Ann Saudi Med. 2008, 28 (4): 292-293. 10.4103\/0256-4947.51714","journal-title":"Ann Saudi Med"},{"key":"124_CR8","unstructured":"Samayz.http:\/\/www.samayz-ksa.com\/index.html"},{"issue":"2","key":"124_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0256-4947.51791","volume":"29","author":"R Meenakshisundaram","year":"2009","unstructured":"Meenakshisundaram R, Uma A, Thirumalaikolundusubramanian P: RE: Snake venom preparation for drug-resistant human immunodeficiency virus. Ann Saudi Med. 2009, 29 (2): 159- 10.4103\/0256-4947.51791","journal-title":"Ann Saudi Med"},{"issue":"Pt 4","key":"124_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1099\/0022-1317-79-4-731","volume":"79","author":"M Wachinger","year":"1998","unstructured":"Wachinger M, Kleinschmidt A, Winder D, von Pechmann N, Ludvigsen A, Neumann M, Holle R, Salmons B, Erfle V, Brack-Werner R: Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J Gen Virol. 1998, 79 (Pt 4): 731-740.","journal-title":"J Gen Virol"},{"issue":"5","key":"124_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1172\/JCI6915","volume":"104","author":"D Fenard","year":"1999","unstructured":"Fenard D, Lambeau G, Valentin E, Lefebvre JC, Lazdunski M, Doglio A: Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. J Clin Invest. 1999, 104 (5): 611-618. 10.1172\/JCI6915","journal-title":"J Clin Invest"},{"issue":"3","key":"124_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1128\/JVI.01790-06","volume":"81","author":"JO Kim","year":"2007","unstructured":"Kim JO, Chakrabarti BK, Guha-Niyogi A, Louder MK, Mascola JR, Ganesh L, Nabel GJ: Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J Virol. 2007, 81 (3): 1444-1450. 10.1128\/JVI.01790-06","journal-title":"J Virol"},{"issue":"6686","key":"124_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/31405","volume":"393","author":"PD Kwong","year":"1998","unstructured":"Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998, 393 (6686): 648-659. 10.1038\/31405","journal-title":"Nature"},{"issue":"1","key":"124_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF01702346","volume":"7","author":"A S\u00f6nnerborg","year":"1993","unstructured":"S\u00f6nnerborg A, Johansson B: The neurotoxin-like sequence of human immunodeficiency virus GP120: A comparison of sequence data from patients with and without neurological symptoms. Virus Genes. 1993, 7 (1): 23-31. 10.1007\/BF01702346","journal-title":"Virus Genes"},{"issue":"3","key":"124_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF01310756","volume":"114","author":"P Neri","year":"1990","unstructured":"Neri P, Bracci L, Rustici M, Santucci A: Sequence homology between HIV gp120, rabies virus glycoprotein, and snake venom neurotoxins. Archives of Virology. 1990, 114 (3): 265-269. 10.1007\/BF01310756","journal-title":"Archives of Virology"},{"issue":"2","key":"124_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.toxicon.2007.03.024","volume":"50","author":"JO da Silva","year":"2007","unstructured":"da Silva JO, Fernandes RS, Ticli FK, Oliveira CZ, Mazzi MV, Franco JJ, Giuliatti S, Pereira PS, Soares AM, Sampaio SV: Triterpenoid saponins, new metalloprotease snake venom inhibitors isolated from Pentaclethra macroloba. Toxicon. 2007, 50 (2): 283-291. 10.1016\/j.toxicon.2007.03.024","journal-title":"Toxicon"},{"key":"124_CR17","unstructured":"Esperanza NeuroPeptides.http:\/\/www.esperanzapeptide.net\/news.php"},{"issue":"3","key":"124_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.bbrc.2003.08.044","volume":"309","author":"YJ Zhang","year":"2003","unstructured":"Zhang YJ, Wang JH, Lee WH, Wang Q, Liu H, Zheng YT, Zhang Y: Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity. Biochem Biophys Res Commun. 2003, 309 (3): 598-604. 10.1016\/j.bbrc.2003.08.044","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"124_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0041-0101(02)00102-2","volume":"40","author":"XY Du","year":"2002","unstructured":"Du XY, Clemetson KJ: Snake venom L-amino acid oxidases. Toxicon. 2002, 40 (6): 659-665. 10.1016\/S0041-0101(02)00102-2","journal-title":"Toxicon"},{"issue":"4","key":"124_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/infdis\/172.4.1091","volume":"172","author":"AE Brown","year":"1995","unstructured":"Brown AE, Vahey MT, Zhou SY, Chung RC, Ruiz NM, Hofheinz D, Lane JR, Mayers DL: Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study Group. J Infect Dis. 1995, 172 (4): 1091-1095.","journal-title":"J Infect Dis"},{"key":"124_CR21","unstructured":"Ophidia products Inc.http:\/\/ophidia.com\/novel_synth.html"},{"key":"124_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1172\/JCI6915","volume":"104","author":"DL Fenard","year":"1999","unstructured":"Fenard DL, Valentin E, Lefebvre JC, Lazdunski M, Doglio A: Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. J Clin Invest. 1999, 104: 611-618. 10.1172\/JCI6915","journal-title":"J Clin Invest"},{"issue":"1","key":"124_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0253-7613.19847","volume":"38","author":"V Tandon","year":"2006","unstructured":"Tandon V, Kapoor B, Bano G, Gupta S, Gillani Z, Kour D: P-glycoprotein: Pharmacological relevance. Indian Journal of Pharmacology. 2006, 38 (1): 13-24. 10.4103\/0253-7613.19847.","journal-title":"Indian Journal of Pharmacology"},{"issue":"13","key":"124_CR24","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/S0028-3908(00)00139-8","volume":"39","author":"MI Damaj","year":"2000","unstructured":"Damaj MI, Meyer EM, Martin BR: The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology. 2000, 39 (13): 2785-2791. 10.1016\/S0028-3908(00)00139-8","journal-title":"Neuropharmacology"},{"issue":"10","key":"124_CR25","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1517\/13543784.10.10.1819","volume":"10","author":"MW Decker","year":"2001","unstructured":"Decker MW, Meyer MD, Sullivan JP: The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001, 10 (10): 1819-1830. 10.1517\/13543784.10.10.1819","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"124_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0006-291X(03)00155-4","volume":"302","author":"AM Soares","year":"2003","unstructured":"Soares AM, Marcussi S, Stabeli RG, Franca SC, Giglio JR, Ward RJ, Arantes EC: Structural and functional analysis of BmjMIP, a phospholipase A2 myotoxin inhibitor protein from Bothrops moojeni snake plasma. Biochem Biophys Res Commun. 2003, 302 (2): 193-200. 10.1016\/S0006-291X(03)00155-4","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"124_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0361-9230(99)00027-1","volume":"49","author":"AA Farooqui","year":"1999","unstructured":"Farooqui AA, Litsky ML, Farooqui T, Horrocks LA: Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull. 1999, 49 (3): 139-153. 10.1016\/S0361-9230(99)00027-1","journal-title":"Brain Res Bull"},{"issue":"1","key":"124_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.1365-2753.2002.00315.x","volume":"8","author":"GP Samsa","year":"2002","unstructured":"Samsa GP, Matchar DB, Williams GR, Levy DE: Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT). J Eval Clin Pract. 2002, 8 (1): 61-70. 10.1046\/j.1365-2753.2002.00315.x","journal-title":"J Eval Clin Pract"},{"issue":"5","key":"124_CR29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/mol.59.5.1333","volume":"59","author":"CH Yeh","year":"2001","unstructured":"Yeh CH, Peng HC, Yang RS, Huang TF: Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Molecular pharmacology. 2001, 59 (5): 1333-1342.","journal-title":"Molecular pharmacology"},{"issue":"10","key":"124_CR30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/0041-0101(92)90439-C","volume":"30","author":"BS Basavarajappa","year":"1992","unstructured":"Basavarajappa BS, Gowda TV: Comparative characterization of two toxic phospholipases A2 from Indian cobra (Naja naja naja) venom. Toxicon. 1992, 30 (10): 1227-1238. 10.1016\/0041-0101(92)90439-C","journal-title":"Toxicon"},{"issue":"4","key":"124_CR31","first-page":"1033","volume":"8","author":"JE Cura","year":"2002","unstructured":"Cura JE, Blanzaco DP, Brisson C, Cura MA, Cabrol R, Larrateguy L, Mendez C, Sechi JC, Silveira JS, Theiller E: Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. Clin Cancer Res. 2002, 8 (4): 1033-1041.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"124_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/00001813-199710000-00003","volume":"8","author":"LA Costa","year":"1997","unstructured":"Costa LA, Miles HA, Diez RA, Araujo CE, Coni Molina CM, Cervellino JC: Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: safety and pharmacokinetic data. Anti-cancer drugs. 1997, 8 (9): 829-834. 10.1097\/00001813-199710000-00003","journal-title":"Anti-cancer drugs"},{"issue":"1","key":"124_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1432-1033.1988.tb13977.x","volume":"173","author":"R Bazzo","year":"1988","unstructured":"Bazzo R, Tappin MJ, Pastore A, Harvey TS, Carver JA, Campbell ID: The structure of melittin. A 1H-NMR study in methanol. Eur J Biochem. 1988, 173 (1): 139-146. 10.1111\/j.1432-1033.1988.tb13977.x","journal-title":"Eur J Biochem"},{"key":"124_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev.iy.13.040195.000425","volume":"13","author":"HG Boman","year":"1995","unstructured":"Boman HG: Peptide antibiotics and their role in innate immunity. Annu Rev Immunol. 1995, 13: 61-92. 10.1146\/annurev.iy.13.040195.000425","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"124_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1399-3011.1992.tb00321.x","volume":"40","author":"D Wade","year":"1992","unstructured":"Wade D, Andreu D, Mitchell SA, Silveira AM, Boman A, Boman HG, Merrifield RB: Antibacterial peptides designed as analogs or hybrids of cecropins and melittin. Int J Pept Protein Res. 1992, 40 (5): 429-436.","journal-title":"Int J Pept Protein Res"},{"issue":"26","key":"124_CR36","doi-asserted-by":"publisher","first-page":"12466","DOI":"10.1073\/pnas.92.26.12466","volume":"92","author":"JF Marcos","year":"1995","unstructured":"Marcos JF, Beachy RN, Houghten RA, Blondelle SE, Perez-Paya E: Inhibition of a plant virus infection by analogs of melittin. Proc Natl Acad Sci USA. 1995, 92 (26): 12466-12469. 10.1073\/pnas.92.26.12466","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"124_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0196-9781(96)00290-2","volume":"18","author":"A Baghian","year":"1997","unstructured":"Baghian A, Jaynes J, Enright F, Kousoulas KG: An amphipathic alpha-helical synthetic peptide analogue of melittin inhibits herpes simplex virus-1 (HSV-1)-induced cell fusion and virus spread. Peptides. 1997, 18 (2): 177-183. 10.1016\/S0196-9781(96)00290-2","journal-title":"Peptides"},{"issue":"11","key":"124_CR38","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1073\/pnas.76.11.5843","volume":"76","author":"AF Esser","year":"1979","unstructured":"Esser AF, Bartholomew RM, Jensen FC, Muller-Eberhard HJ: Disassembly of viral membranes by complement independent of channel formation. Proc Natl Acad Sci USA. 1979, 76 (11): 5843-5847. 10.1073\/pnas.76.11.5843","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"124_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0014-5793(92)80780-K","volume":"309","author":"M Wachinger","year":"1992","unstructured":"Wachinger M, Saermark T, Erfle V: Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells. FEBS letters. 1992, 309 (3): 235-241. 10.1016\/0014-5793(92)80780-K","journal-title":"FEBS letters"},{"issue":"2","key":"124_CR40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/mol.60.2.341","volume":"60","author":"D Fenard","year":"2001","unstructured":"Fenard D, Lambeau G, Maurin T, Lefebvre JC, Doglio A: A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol Pharmacol. 2001, 60 (2): 341-347.","journal-title":"Mol Pharmacol"},{"issue":"19","key":"124_CR41","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1157\/13069312","volume":"123","author":"VGCL Villarubia","year":"2004","unstructured":"Villarubia VGCL, Diez RA: Secreted phospholipases A2 (sPLA2): friends or foes? Are they actors in antibacterial and anti-HIV resistance?. Med Clin (Barc). 2004, 123 (19): 749-757. 10.1157\/13069312","journal-title":"Med Clin (Barc)"},{"issue":"11","key":"124_CR42","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1074\/jbc.275.11.7492","volume":"275","author":"E Valentin","year":"2000","unstructured":"Valentin E, Ghomashchi F, Gelb MH, Lazdunski M, Lambeau G: Novel human secreted phospholipase A(2) with homology to the group III bee venom enzyme. J Biol Chem. 2000, 275 (11): 7492-7496. 10.1074\/jbc.275.11.7492","journal-title":"J Biol Chem"},{"issue":"8","key":"124_CR43","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1074\/jbc.M109699200","volume":"277","author":"RS Koduri","year":"2002","unstructured":"Koduri RS, Gronroos JO, Laine VJ, Le Calvez C, Lambeau G, Nevalainen TJ, Gelb MH: Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A(2). J Biol Chem. 2002, 277 (8): 5849-5857. 10.1074\/jbc.M109699200","journal-title":"J Biol Chem"},{"issue":"3","key":"124_CR44","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1073\/pnas.96.3.1030","volume":"96","author":"SA Stranford","year":"1999","unstructured":"Stranford SA, Skurnick J, Louria D, Osmond D, Chang SY, Sninsky J, Ferrari G, Weinhold K, Lindquist C, Levy JA: Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA. 1999, 96 (3): 1030-1035. 10.1073\/pnas.96.3.1030","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-6405-6-25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:29:53Z","timestamp":1630456193000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/1742-6405-6-25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,19]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1186\/1742-6405-6-25","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,19]]},"assertion":[{"value":"24 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"25"}}